Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs

Related articles

Scientist sitting at a bench

eBlogs

10
29
25

Why outdated RNA characterization assays fall short for regulatory readiness

In this eBlog, discover how sequencing-based methods provide a complete view of RNA quality, enabling confident assessment of identity, purity, and integrity to support both research and regulatory readiness.

read more
Representation of a nanopore for sequencing

eBlogs

09
20
25

Direct RNA sequencing for RNA therapeutic quality control

Direct RNA sequencing provides unique insights into RNA biology. Learn more about how this technology is being applied to advance discovery and ensure rigorous quality control for RNA medicines.

read more
Eclipsebio presented at the mRNA Therapeutics Summit

eBlogs

08
15
25

The future of RNA medicines at the 5th mRNA Therapeutics Summit

The 5th Annual mRNA Therapeutics Summit brought together leaders from biotech, pharma, and academia to discuss the breakthroughs shaping RNA medicines and the bottlenecks that remain. Our recap highlights key takeaways, emerging opportunities, and the trends likely to define the next decade of RNA therapeutic development.

read more

eBlogs

07
25
25

Small proteins, big health impacts – the biology of micropeptides

Micropeptides, proteins under 100 amino acids, are emerging regulators of cancer, metabolism, and neurodegeneration. Learn how ribosome profiling can reveal these hidden proteins, driving the discovery of new biomarkers and development of novel therapeutics.

read more